{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:35:34Z","timestamp":1783038934098,"version":"3.54.6"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.nefroe.2026.501414","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T12:15:23Z","timestamp":1770293723000},"page":"501414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Healthcare resource utilization and costs of chronic kidney disease in Spain across KDIGO categories: Insights from real-world evidence"],"prefix":"10.1016","volume":"46","author":[{"given":"Rafael","family":"Santamaria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5584-4735","authenticated-orcid":false,"given":"Carlos","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unai","family":"Aranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Capel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Cebri\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Alc\u00e1zar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Gorostidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2026.501414_bib0255","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns","volume":"105","author":"Levin","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2026.501414_bib0260","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"Kalantar-Zadeh","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.nefroe.2026.501414_bib0265","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.medcli.2020.03.005","article-title":"Prevalence of chronic kidney disease and associated factors in the Spanish population attended in primary care: results of the IBERICAN study","volume":"156","author":"Llisterri","year":"2021","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.nefroe.2026.501414_bib0270","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.nefro.2024.12.009","article-title":"Magnitude of chronic kidney disease in Spain","volume":"45","author":"Santamaria","year":"2025","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2026.501414_bib0275","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1093\/ckj\/sfac168","article-title":"Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort","volume":"15","author":"Pollock","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2026.501414_bib0280","doi-asserted-by":"crossref","first-page":"e2351518","DOI":"10.1001\/jamanetworkopen.2023.51518","article-title":"Early-stage chronic kidney disease and related health care spending","volume":"7","author":"Sakoi","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.nefroe.2026.501414_bib0285","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ekir.2023.01.037","article-title":"Health care resource utilization and related costs of patients with CKD from the United States: a report from the DISCOVER CKD retrospective cohort","volume":"8","author":"Garcia Sanchez","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2026.501414_bib0290","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1186\/s12913-021-06566-2","article-title":"Costs and healthcare utilisation of patients with chronic kidney disease in Spain","volume":"21","author":"Escobar","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.nefroe.2026.501414_bib0295","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1080\/13696998.2020.1830782","article-title":"Chronic kidney disease in Spain: analysis of patient characteristics, incidence and direct medical costs (2011\u20132017)","volume":"23","author":"Darb\u00e0","year":"2020","journal-title":"J Med Econ"},{"key":"10.1016\/j.nefroe.2026.501414_bib0300","doi-asserted-by":"crossref","first-page":"e70189","DOI":"10.1111\/ctr.70189","article-title":"Economic impact of dementia after kidney transplantation: a matched cohort analysis","volume":"39","author":"Lentine","year":"2025","journal-title":"Clin Transplant"},{"key":"10.1016\/j.nefroe.2026.501414_bib0305","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12913-020-4960-x","article-title":"Direct medical costs of end-stage kidney disease and renal replacement therapy: a cohort study in Guangzhou City, southern China","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.nefroe.2026.501414_bib0310","doi-asserted-by":"crossref","first-page":"10730","DOI":"10.1038\/s41598-023-37814-6","article-title":"Healthcare costs after kidney transplantation compared to dialysis based on propensity score methods and real world longitudinal register data from Sweden","volume":"13","author":"Zhang","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.nefroe.2026.501414_bib0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.nefro.2025.501340","article-title":"Cardiovascular and renal outcomes according across to KDIGO stages of chronic kidney disease in the Spanish population: insights from real-world evidence","author":"Santamaria","year":"2025","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2026.501414_bib0320","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/j.ajkd.2020.07.013","article-title":"Burden and cost of caring for US veterans with CKD: initial findings from the VA renal information system (VA-REINS)","volume":"77","author":"Saran","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2026.501414_bib0325","first-page":"1506","article-title":"Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database","volume":"26","author":"Folkerts","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.nefroe.2026.501414_bib0330","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s12916-022-02427-9","article-title":"Costs of multimorbidity: a systematic review and meta-analyses","volume":"20","author":"Tran","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.nefroe.2026.501414_bib0335","doi-asserted-by":"crossref","first-page":"788","DOI":"10.7326\/M22-3228","article-title":"Population-wide screening for chronic kidney disease: a cost-effectiveness analysis","volume":"176","author":"Cusick","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nefroe.2026.501414_bib0340","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jama.2024.26790","article-title":"Tracking US health care spending by health condition and county","volume":"333","author":"Dieleman","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.nefroe.2026.501414_bib0345","doi-asserted-by":"crossref","first-page":"9853","DOI":"10.3390\/ijerph18189853","article-title":"Cost of type 2 diabetes patients with chronic kidney disease based on real-world data: an observational population-based study in Spain","volume":"18","author":"Us\u00f3-Talamantes","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.nefroe.2026.501414_bib0350","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41366-023-01376-4","article-title":"Real-world costs of obesity-related complications over eight years: a US retrospective cohort study in 28,500 individuals","volume":"47","author":"Pearson-Stuttard","year":"2023","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.nefroe.2026.501414_bib0355","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/ndt\/gfac140","article-title":"High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database","volume":"38","author":"Fried","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2026.501414_bib0360","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.recesp.2020.09.014","article-title":"Epidemiology and treatment of heart failure in Spain: the HF-PATHWAYS study","volume":"75","author":"Sicras-Mainar","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.nefroe.2026.501414_bib0365","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1186\/s12913-020-05828-9","article-title":"Costs and healthcare utilisation of patients with heart failure in Spain","volume":"20","author":"Escobar","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.nefroe.2026.501414_bib0370","unstructured":"The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC\/DDD): World Health Organization. Available from: https:\/\/www.who.int\/standards\/classifications\/other-classifications\/the-anatomical-therapeutic-chemical-classification-system-with-defined-daily-doses [accessed 15.2.24]."},{"key":"10.1016\/j.nefroe.2026.501414_bib0375","unstructured":"Database of Spanish Healthcare Costs and Cost-Effectiveness Ratios: eSalud; Oblikue Consulting, S.L: Barcelona, Spain, 2007; Available from: http:\/\/esalud.oblikue.com\/ [accessed 15.2.24]."},{"key":"10.1016\/j.nefroe.2026.501414_bib0380","unstructured":"BOTPLUS Database General Council of Pharmacist Colleges. Available from: https:\/\/botplusweb.farmaceuticos.com\/ [accessed 15.2.24]."},{"key":"10.1016\/j.nefroe.2026.501414_bib0385","unstructured":"Costs of Absence from Work in Spain. Available from: https:\/\/www.ine.es\/dynt3\/inebase\/index.htm?padre=4563&capsel=4563 [accessed 15.2.24]."},{"key":"10.1016\/j.nefroe.2026.501414_bib0390","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4103\/2155-8213.190481","article-title":"Three common misuses of P values","volume":"7","author":"Kim","year":"2016","journal-title":"Dent Hypotheses"},{"key":"10.1016\/j.nefroe.2026.501414_bib0395","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.nefroe.2018.04.010","article-title":"Chronic kidney disease in Spain: prevalence and impact of accumulation of cardiovascular risk factors","volume":"38","author":"Gorostidi","year":"2018","journal-title":"Nefrologia (Engl Ed)"},{"key":"10.1016\/j.nefroe.2026.501414_bib0400","first-page":"e41","article-title":"2025 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"151","author":"Martin","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.nefroe.2026.501414_bib0405","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.pharma.2024.01.002","article-title":"Chronic kidney disease in America, Africa, and Asia: overview of treatment cost and options","volume":"82","author":"Mourchid","year":"2024","journal-title":"Ann Pharm Fr"},{"key":"10.1016\/j.nefroe.2026.501414_bib0410","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2026.501414_bib0415","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2026.501414_bib0420","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nefroe.2026.501414_bib0425","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s41999-024-01086-8","article-title":"Healthcare costs in relation to kidney function among older people: the SCOPE study","volume":"16","author":"Balducci","year":"2025","journal-title":"Eur Geriatr Med"},{"key":"10.1016\/j.nefroe.2026.501414_bib0430","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1186\/s12913-023-10424-8","article-title":"Managing comorbidities in chronic kidney disease reduces utilization and costs","volume":"23","author":"Li","year":"2023","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.nefroe.2026.501414_bib0435","first-page":"gfae242","article-title":"Characteristics, treatment and disease burden among stage 3\u20134 chronic kidney disease patients with and without type 2 diabetes in Finland during 2016\u20132022","author":"Mets\u00e4rinne","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2026.501414_bib0440","doi-asserted-by":"crossref","first-page":"662544","DOI":"10.3389\/fphar.2021.662544","article-title":"Systematic review and meta-analysis of renin\u2013angiotensin\u2013aldosterone system blocker effects on the development of cardiovascular disease in patients with chronic kidney disease","volume":"12","author":"Yanai","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.nefroe.2026.501414_bib0445","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2026.501414_bib0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.kint.2025.04.005","article-title":"Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","author":"Ortiz","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2026.501414_bib0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102426","article-title":"Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study","volume":"68","author":"Forbes","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.nefroe.2026.501414_bib0460","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.ekir.2022.05.033","article-title":"Low adherence to kidney disease: improving global outcomes 2012 CKD clinical practice guidelines despite clear evidence of utility","volume":"7","author":"James","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2026.501414_bib0465","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1007\/s12325-023-02608-9","article-title":"Global economic burden associated with chronic kidney disease: a pragmatic review of medical costs for the inside CKD research programme","volume":"40","author":"Jha","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.nefroe.2026.501414_bib0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100873","article-title":"Healthcare costs across diabetic kidney disease stages: a Veterans affairs study","volume":"6","author":"Kim","year":"2024","journal-title":"Kidney Med"},{"key":"10.1016\/j.nefroe.2026.501414_bib0475","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2337\/dc20-1913","article-title":"Worldwide epidemiology of diabetes-related end-stage renal disease, 2000\u20132015","volume":"44","author":"Cheng","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.nefroe.2026.501414_bib0480","first-page":"1","article-title":"The cost and outcomes of using multidisciplinary care program in the care of adult patients with advanced chronic kidney disease","author":"Kwek","year":"2025","journal-title":"Nephron"},{"key":"10.1016\/j.nefroe.2026.501414_bib0485","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1186\/s12882-024-03901-7","article-title":"Economic evaluation of adding dapagliflozin to standard care in the treatment of chronic kidney disease: a systematic review","volume":"25","author":"Wang","year":"2024","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefroe.2026.501414_bib0490","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.nefroe.2024.11.009","article-title":"Projection of the clinical and economic burden of chronic kidney disease between 2022 and 2027 in Spain: results of the Inside CKD project","volume":"44","author":"Navarro Gonz\u00e1lez","year":"2024","journal-title":"Nefrologia (Engl Ed)"},{"key":"10.1016\/j.nefroe.2026.501414_bib0495","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12889-023-17338-4","article-title":"Association between prevalence and severity of chronic kidney disease and employment status: a nationwide study in Korea","volume":"24","author":"Choi","year":"2024","journal-title":"BMC Public Health"},{"key":"10.1016\/j.nefroe.2026.501414_bib0500","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1681\/ASN.2020081148","article-title":"The preventable productivity burden of kidney disease in Australia","volume":"32","author":"Savira","year":"2021","journal-title":"J Am Soc Nephrol"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251426000192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251426000192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T04:26:38Z","timestamp":1770697598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251426000192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2013251426000192"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2026.501414","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Healthcare resource utilization and costs of chronic kidney disease in Spain across KDIGO categories: Insights from real-world evidence","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2026.501414","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501414"}}